Ticker Details
Geron Corporation Geron Corp is a biopharmaceutical company. It supports the clinical stage development of a telomerase inhibitor, imetelstat.
IPO Date:	July 31, 1996
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$737.75M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.13 | 3.40%
Avg Daily Range (30 D):	$0.04 | 2.75%
Avg Daily Range (90 D):	$0.06 | 3.54%

Institutional Daily Volume
Avg Daily Volume:	3.12M
Avg Daily Volume (30 D):	12.98M
Avg Daily Volume (90 D):	15.53M

Trade Size
Avg Trade Size (Sh.):	354
Avg Trade Size (Sh.) (30 D):	179
Avg Trade Size (Sh.) (90 D):	360

Institutional Trades
Total Institutional Trades:	2,961
Avg Institutional Trade:	$1.82M
Avg Institutional Trade (30 D):	$1.27M
Avg Institutional Trade (90 D):	$1.72M
Avg Institutional Trade Volume:	.65M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.18M
Avg Closing Trade (30 D):	$1.16M
Avg Closing Trade (90 D):	$1.46M
Avg Closing Volume:	820.18K

News

May 20, 2026 @ 1:50 PM Cell-Based Therapies Poised to Disrupt Multi-Billi... Source: Market News Updates

Apr 22, 2026 @ 11:00 AM Geron Plans to Announce First Quarter 2026 Financi... Source: Na

Apr 13, 2026 @ 12:00 PM Geron Announces Appointment of Timothy Williams as... Source: Geron Corporation

Apr 6, 2026 @ 12:00 PM Geron to Participate in the 25th Annual Needham Vi... Source: Na

Feb 25, 2026 @ 12:00 PM Geron Corporation Reports Fourth Quarter and Full ... Source: Na

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.11	$-.01	$-.05
Diluted EPS	$-.11	$-.01	$-.05
Revenue	$196.12M	$51.84M	$48.02M
Gross Profit
Net Income / Loss	$-67.31M	$-3.64M	$-28.86M
Operating Income / Loss	$-51.72M	$.16M	$-25.54M
Cost of Revenue
Net Cash Flow	$-14.83M	$-8.66M	$-.55M
PE Ratio